- Q2 2024 TCM Group A/S Earnings Call TranscriptAug 21, 2024kr64.4 (+1.26%)Earnings
- Q1 2024 TCM Group A/S Earnings Call TranscriptMay 16, 2024kr57 (+8.37%)Earnings
- Q4 2023 TCM Group A/S Earnings Call TranscriptFeb 28, 2024kr50.6 (+2.22%)Earnings
- TCM Group A/S Conference Call TranscriptOct 19, 2023
- Q2 2023 TCM Group A/S Earnings Call TranscriptAug 18, 2023kr62.2 (-3.42%)Earnings
- Q3 2022 TCM Group A/S Earnings Call TranscriptNov 15, 2022kr68.5 (-5.65%)Earnings
- Q2 2022 TCM Group A/S Earnings Call TranscriptAug 19, 2022kr85 (-5.56%)Earnings
- Q1 2022 TCM Group A/S Earnings Call TranscriptMay 18, 2022kr107 (+5.31%)Earnings
- Full Year 2021 TCM Group A/S Earnings Call TranscriptFeb 25, 2022kr124 (+0.40%)Earnings
- Q3 2021 TCM Group A/S Earnings Call TranscriptNov 12, 2021kr158 (-3.07%)Earnings
- Q2 2021 TCM Group A/S Earnings Call TranscriptAug 20, 2021kr158 (+2.60%)Earnings
- Q1 2021 TCM Group A/S Earnings Call TranscriptMay 19, 2021kr164 (-4.93%)Earnings
- Q4 2020 TCM Group A/S Earnings Call TranscriptFeb 24, 2021kr144.5 (-4.30%)Earnings
- Q3 2020 TCM Group A/S Earnings Call TranscriptNov 11, 2020kr128.5 (-4.46%)Earnings
- Q2 2020 Tcm Group A/S Earnings Call TranscriptAug 18, 2020kr129.5 (-5.47%)Earnings
- Q1 2020 Tcm Group A/S Earnings Call TranscriptMay 06, 2020kr94.6 (-1.87%)Earnings
- Q4 2019 Tcm Group A/S Earnings Call TranscriptFeb 26, 2020kr125 (-8.76%)Earnings
- Q3 2019 Tcm Group A/S Earnings Call TranscriptNov 06, 2019kr112 (+0.90%)Earnings
- Q2 2019 Tcm Group A/S Earnings Call TranscriptAug 14, 2019kr112 (+1.36%)Earnings
- Q1 2019 Tcm Group A/S Earnings Call TranscriptMay 07, 2019kr110 (-1.35%)Earnings
Q1 2024 TCM Group A/S Earnings Call Transcript
/- -
Good morning, ladies and gentlemen, and welcome to the presentation of the Q1 results for TCM Group presented us today our CFO, Thomas Young, and myself, CEO, Torben polling. We will comment on the business and the financial results, after which we will hand over to the operator for the Q&A session.
Let us start the presentation and turn to page 2 for the business update. Sales in the first quarter were developed in line with our expectations that improved order intake from the B2C market in Denmark. Whereas, B2B sales, as expected, contracted primarily within project sales and housebuilders revenue increased by 11% in the quarter due to the inclusion of albuterol. However, with an organic decline of 12% on a like-for-like basis, order intake in Denmark was up 3% compared to Q1 last year would be to see order intake growing by more than 10%. The improvement in gross margin compared to last year Q1 was driven by the changed sales mix and the inclusion of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)